Estimation of an appropriate dose of trazodone for paediatric insomnia, and the potential for a trazodone-atomoxetine interaction.
There is a paucity of clinical trials for the treatment of paediatric insomnia. This study was designed to predict doses of trazodone to guide dosing in a clinical trial for paediatric insomnia, using physiologically based pharmacokinetic (PBPK) modelling. Data on the pharmacokinetics of trazodone in children is currently lacking. The interaction potential between trazodone and atomoxetine was also predicted. Doses predicted in the following age groups, with exposures corresponding to adult dosages of 30 mg, 75 mg and 150 mg once-a-day (QD) respectively were: 2-6 yr old group: doses of 0.35, 0.8 and 1.6 mg/kg QD. >6-12 yr old group: doses of 0.4, 1.0 and 1.9 mg/kg QD. >12-17 yr old group: doses of 0.4, 1.1 and 2.1 mg/kg QD. An interaction between trazodone and atomoxetine was predicted to be unlikely. Clinical trials based on the above predicted dosing are currently in progress and pharmacokinetic data obtained will enable further refinement of the PBPK models.